Targeting immunosuppression by TGF-β1 for cancer immunotherapy.

"Declaration of Competing Interest The authors declare the following financial competing interests: Patents pertaining to anti-GARP:TGF-β1 antibodies discussed in the review article have been filed under the Patent Cooperation Treaty (international application Numbers PCT/EP2014/066650 and PCT/1B2019/053753), with Sophie Lucas and Grégoire de Streel as inventors and UCLouvain as applicant."

"We thank E. Hemelrike for editorial assistance. G.d.S. was supported by a FRIA fellowship (F.R.S.-FNRS). Research work in the laboratory of S.L. and cited in this review was supported by grants from the Fondation contre le Cancer (grant F/2016/837), from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant TARG-SUP 682818), from the Actions de Recherche Concertées (grant 14/19-056), from the Fonds National de la Recherche Scientifique (PDR number T.0089.16) and from Région Wallonne (program WALinnov, project IMMUCAN, convention number 1610119)."